Sparks - IRLAB Therapeutics

IRLAB Therapeutics has reported positive top-line data from one of two ongoing Phase I studies evaluating the drug candidate IRL757 as a treatment for apathy. This study, financed by the McQuade Center for Strategic Research and Development (MSRD), assessed the pharmacokinetics, safety and tolerability of single ascending oral doses of IRL757 in healthy older adults (>65 years). The second Phase I study (in healthy younger participants), which is funded by a US$2m grant from the Michael J Fox Foundation for Parkinson’s Research, is expected to readout in H125 (multiple ascending dose portion ongoing), with further development efforts (through proof of concept) to be supported by MSRD.

The most significant upcoming catalyst for IRLAB will be finalisation of a collaboration or out-licensing partnership for its lead asset, mesdopetam, with an update expected imminently. The company will report its full-year FY24 results on 12 February 2025.